Affimed NV (Affimed NV) EBIT per Share : $-7.51 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV EBIT per Share?

Affimed NV's EBIT per Share for the three months ended in Dec. 2023 was $-1.44. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.51.

During the past 3 years, the average EBIT per Share Growth Rate was -16.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was -12.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Affimed NV's EBIT per Share or its related term are showing as below:

AFMD' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -16.7 Med: -5.4 Max: 22.2
Current: -16.7

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Affimed NV was 22.20% per year. The lowest was -16.70% per year. And the median was -5.40% per year.

AFMD's 3-Year EBIT Growth Rate is ranked worse than
72.26% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs AFMD: -16.70

Affimed NV's EBIT for the three months ended in Dec. 2023 was $-21.59 Mil.

Affimed NV EBIT per Share Historical Data

The historical data trend for Affimed NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV EBIT per Share Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-5.51

-6.02

-5.37

-6.28

-7.60

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-2.34	-2.26	-2.10	-1.71	-1.44

Affimed NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Affimed NV's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-113.554	/	14.940
=	-7.60

Affimed NV's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-21.585	/	14.958
=	-1.44

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.51

Affimed NV (NAS:AFMD) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Affimed NV EBIT per Share Related Terms

Thank you for viewing the detailed overview of Affimed NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.